<DOC>
	<DOCNO>NCT00521742</DOCNO>
	<brief_summary>The purpose study evaluate cardiovascular effect pioglitazone , daily ( QD ) , versus glyburide administer patient type 2 diabetes mellitus mild cardiac disease .</brief_summary>
	<brief_title>Efficacy Pioglitazone Compared Glyburide Treating Subjects With Type 2 Diabetes Mellitus Mild Cardiac Disease</brief_title>
	<detailed_description>Diabetes chronic disease involve multiple metabolic defect include inadequate insulin activity resultant hyperglycemia . Individuals ' differ genetic predisposition , level physical activity , age contribute variation onset severity type 2 diabetes . However , progression disease typically follow characteristic pattern begin reduced sensitivity hepatic peripheral-tissues circulate insulin ( ie , insulin resistance ) . The body 's decreasing ability produce adequate insulin overcome insulin resistance ( ie , insulin deficiency due beta-cell insufficiency ) result impair glucose tolerance ultimately overt diabetes . In United States , estimate 17 million people diabetes , type 2 diabetes occur approximately 90 % 95 % case . The goal treat type 2 diabetes control blood glucose thereby prevent long-term complication . Adequate glycemic control paramount attempt avert chronic complication , include blindness , renal dysfunction resultant dialysis renal transplantation , neuropathy , nontraumatic amputation . Intensive glucose management early stage diabetes may help forestall complication . Pioglitazone thiazolidinedione develop Takeda Chemical Industries , Ltd. Glyburide , oral antidiabetic agent sulfonylurea class . The primary purpose study evaluate cardiovascular effect pioglitazone versus glyburide administer patient type 2 diabetes mellitus mild cardiac disease Study participation anticipate approximately 1 year 2 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Diagnosed type 2 diabetes mellitus . Naive oral antidiabetic pharmacologic therapy , currently take sulfonylurea monotherapy , currently take sulfonylurea/metformin combination therapy , currently take metformin monotherapy . Mild cardiac disease New York Heart Association functional Class I . Participated dietary counseling . Glycosylated hemoglobin great equal 7.5 % le 12 % Screening na√Øve oral antidiabetic pharmacologic therapy take metformin monotherapy , great equal 6.5 % le 12 % currently take sulfonylurea monotherapy take ulfonylurea/metformin combination therapy . Stable therapy cardiovascular dysfunction , define change therapy great equal 4 week prior Randomization . Within past 30 day treat rosiglitazone , pioglitazone , troglitazone previously treat rosiglitazone , pioglitazone , troglitazone discontinue therapy lack efficacy clinical laboratory sign intolerance . Treated sulfonylurea discontinue lack efficacy clinical laboratory intolerance . Currently take insulin continuous insulin therapy control diabetes Type 1 ( insulindependent ) diabetes mellitus history ketoacidosis . Any investigational drug 30 day prior Visit 1 receive drug timeframe study . History chronic alcoholism drug abuse 6 month prior study . New York Heart Association functional Class II , III , IV cardiac disease Screening , previous history Class III IV . Any following : myocardial infarction coronary angioplasty bypass graft unstable angina pectoris transient ischemic attack document cerebrovascular accident . 9 . Abdominal , thoracic , vascular surgery 3 month prior Visit 1 . Planned surgical catheterization intervention within 6 month follow Visit 1 . Awaiting cardiac transplantation . Intercurrent illness severe enough require hospitalization 3 week prior Visit 1 . Body mass index great 48 kg/m2 calculate [ weight ( kg ) /height ( ) 2 ] . Anemia hemoglobin less 10.5 g per dL men 10.0 g per dL woman . Triglyceride level great 500 mg per dL . Clinical evidence active liver disease alanine transaminase level great 2.5 time upper limit normal . Serum creatinine great 2.0 mg per dL men 1.8 mg per dL woman urinalysis protein ( albumin ) excretion level great 2 plus Combistix equivalent repeat 24hour result great 3 g macroproteinuria . Unstable coronary syndrome . Systolic blood pressure great 160 mm Hg diastolic blood pressure great 90 mm Hg Screening . Serious uncontrolled cardiac rhythm disturbance . Symptomatic orthostatic hypotension systolic blood pressure le 90 mm Hg . Severe , advance peripheral vascular disease ( limbthreatening ischemia ) claudication result inability walk great 1 block climb 10 stair without interruption . Lower extremity amputation would prevent patient perform exercise test . Any serious disease condition might affect lifeexpectancy make difficult successfully manage follow subject accord protocol . Unexplained clinically significant finding chest xray . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Oral , injected , inhaled corticosteroid great 2 week duration , need recurrent u corticosteroid . Prescription niacin Antidiabetic medication except metformin Cardiovascular medication must remain stable least 4 week prior Randomization Nonsteroidal antiinflammatory drug Aspirin great 325 mg per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>